Takeda To Ditch Orexigen In Another Deal Exit?
This article was originally published in PharmAsia News
Executive Summary
It's starting to look like there may be an acrimonious divorce in store for Orexigen and its marketing partner Takeda, now that the Japanese pharma has said it won't pay for another costly cardiovascular outcomes study for their obesity drug Contrave after the first was halted.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.